Hi Stocrates,
Welcome to DXB & great first post!
Your first point: The sparsentan Ph2 was open to recruitment from 8 years old to adults in the USA after Data Safety Monitoring Board review, but only adults in Europe >18 years old.
This actually made me wonder would DMX-200 Ph3 also be open to paediatrics? It’s heartbreaking children need to be on such medication, but what choice is there?
I posted a table of adverse effects from the Spartensan trial over on the other thread & some safety considerations on their current Ph3. Kidney disease causes some nasty symptoms anyway, so anything that is showing good efficacy with minimum adverse effects would obviously be the choice of treatment.
GLTAH
- Forums
- ASX - By Stock
- DXB
- Ann: Trading Halt
Ann: Trading Halt, page-112
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
-0.020(4.44%) |
Mkt cap ! $236.7M |
Open | High | Low | Value | Volume |
44.5¢ | 44.5¢ | 41.8¢ | $972.5K | 2.277M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 92116 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 57364 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 92116 | 0.425 |
8 | 150844 | 0.420 |
3 | 49247 | 0.415 |
7 | 183309 | 0.410 |
7 | 174830 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 57364 | 3 |
0.435 | 16690 | 1 |
0.440 | 27754 | 2 |
0.445 | 191221 | 3 |
0.450 | 93130 | 2 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |